牛牛AI助理已提取核心訊息
Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, has filed a prospectus related to an amended and restated sales agreement with TD Cowen, under which the company may offer and sell shares of its common stock up to an aggregate offering price of $100,000,000. The common stock is listed on the Nasdaq Global Select Market under the symbol 'ARQT.' The sales are to be made in 'at-the-market' equity offerings as defined by Rule 415(a)(4) under the Securities Act of 1933. TD Cowen will act as the sales agent and will receive up to 3.0% of the aggregate gross proceeds from any sales made under the agreement. The company plans to use the net proceeds for general corporate purposes and to fund the continued development and commercialization of its product candidates. The prospectus was dated February 8, 2024, and the last reported sale price of Arcutis' common stock on January 30, 2024, was $5.87 per share.
Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, has filed a prospectus related to an amended and restated sales agreement with TD Cowen, under which the company may offer and sell shares of its common stock up to an aggregate offering price of $100,000,000. The common stock is listed on the Nasdaq Global Select Market under the symbol 'ARQT.' The sales are to be made in 'at-the-market' equity offerings as defined by Rule 415(a)(4) under the Securities Act of 1933. TD Cowen will act as the sales agent and will receive up to 3.0% of the aggregate gross proceeds from any sales made under the agreement. The company plans to use the net proceeds for general corporate purposes and to fund the continued development and commercialization of its product candidates. The prospectus was dated February 8, 2024, and the last reported sale price of Arcutis' common stock on January 30, 2024, was $5.87 per share.
處於商業階段的生物製藥公司Arcutis Biotherapeutics, Inc. 已提交了一份與經修訂和重述的TD Cowen銷售協議相關的招股說明書，根據該協議，該公司可以發行和出售其普通股，總髮行價不超過1億美元。普通股在納斯達克全球精選市場上市，股票代碼爲 “ARQT”。根據1933年《證券法》第415（a）（4）條的定義，銷售將以 “在場” 股票發行中進行。TD Cowen將擔任銷售代理，最多可獲得協議下任何銷售總收益的3.0％。該公司計劃將淨收益用於一般公司用途，併爲其候選產品的持續開發和商業化提供資金。招股說明書的日期爲2024年2月8日，Arcutis普通股最後一次公佈的銷售價格爲每股5.87美元。
處於商業階段的生物製藥公司Arcutis Biotherapeutics, Inc. 已提交了一份與經修訂和重述的TD Cowen銷售協議相關的招股說明書，根據該協議，該公司可以發行和出售其普通股，總髮行價不超過1億美元。普通股在納斯達克全球精選市場上市，股票代碼爲 “ARQT”。根據1933年《證券法》第415（a）（4）條的定義，銷售將以 “在場” 股票發行中進行。TD Cowen將擔任銷售代理，最多可獲得協議下任何銷售總收益的3.0％。該公司計劃將淨收益用於一般公司用途，併爲其候選產品的持續開發和商業化提供資金。招股說明書的日期爲2024年2月8日，Arcutis普通股最後一次公佈的銷售價格爲每股5.87美元。
有用
沒用